Comparison · NCT04732949-2039f1fd
SNG001 vs Placebo: Number of Patients Who Were Intubated or Who Died
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SNG001 vs Placebo: Number of Patients Who Were Intubated or Who Died. Trial comparisons, record NCT04732949-2039f1fd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04732949-2039f1fd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0647 | 0.0423 | 0.0979 | wilson | |
| Risk in group 2 | 0.0732 | 0.0493 | 0.108 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00852 | -0.0495 | 0.0324 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.884 | 0.496 | 1.58 | log | |
| Odds ratio, group 1 over group 2 | 0.876 | 0.471 | 1.63 | log | |
| Number needed to treat, for one fewer participant with the outcome on SNG001 than on Placebo | 117 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SNG001 | Patients received SNG001 via inhalation using nebuliser, once a day for 14 days | 20 | 309 | OG000 |
| Group 2 | Placebo | Patients received Placebo via inhalation using nebuliser, once a day for 14 days | 23 | 314 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Who Were Intubated or Who Died
- Description
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to intubation or death was evaluated. Intubation was defined by the OSCI as a score between 6 and 7. Death was defined by an OSCI score of 8.
- Time frame
- Until Day 35
- Population
- The ITT analysis population consisted of all randomised patients.
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
- NCT number
- NCT04732949
- Phases
- PHASE3
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- SNG001, Placebo
- Lead sponsor
- Synairgen Research Ltd.
- Results first posted
- 2023-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04732949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04732949-2039f1fd